Rilonacept for Recurrent Pericarditis
(RESONANCE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial focuses on individuals with recurrent pericarditis (RP), a condition where the heart's lining becomes inflamed multiple times. The trial aims to understand RP's impact on daily life and health and to evaluate the effectiveness of rilonacept, an anti-inflammatory medication, in real-world settings. Eligible participants must have a doctor-confirmed diagnosis of RP and either currently experience symptoms or have been symptom-free for a while. Those currently affected should have had at least one RP episode in the past three years, while symptom-free individuals should have had no episodes for at least three years.
As a Phase 3 trial, this study represents the final step before FDA approval, allowing participants to contribute to validating a promising treatment.
What is the safety track record for rilonacept?
Studies have shown that rilonacept is safe for people with recurring heart inflammation, known as pericarditis. Research indicates that rilonacept quickly reduces pain and swelling and helps improve quality of life. The FDA has already approved this drug for treating recurrent pericarditis, confirming its safety for this use. Participants in studies who took rilonacept experienced fewer flare-ups than those who did not, suggesting it is generally well-tolerated.12345
Why are researchers excited about this trial?
Unlike other treatments for recurrent pericarditis, which often involve anti-inflammatory medications or corticosteroids, this trial focuses on understanding the natural history of the condition in both pediatric and adult patients. Researchers are excited about this trial because it aims to gather comprehensive data that can lead to better understanding and management of recurrent pericarditis. By studying the progression and characteristics of the condition in various age groups, this registry could pave the way for more personalized and effective treatment strategies in the future.
What evidence suggests that rilonacept might be an effective treatment for recurrent pericarditis?
Research has shown that rilonacept can help treat recurring pericarditis. In one study, rilonacept quickly eased pericarditis episodes and helped patients use fewer steroids. Another study found that this treatment reduced the chances of pericarditis returning. Patients experienced less pain, less swelling, and an improved quality of life. Overall, rilonacept has effectively reduced symptoms and prevented recurrences.56789
Who Is on the Research Team?
John F Paolini, MD, PhD
Principal Investigator
Kiniksa Pharmaceuticals Corp
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Observation
Participants are observed to document RP-related clinical, health-related quality of life, and economic burden, and to generate data on the impact of rilonacept
Follow-up
Participants are monitored for changes in clinical outcomes and adverse events
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kiniksa Pharmaceuticals International, plc
Lead Sponsor
Kiniksa Pharmaceuticals (UK), Ltd.
Industry Sponsor